Hansoh Pharmaceutical Group Co Limited/ADR
HNPHYDrugs in Pipeline
9
Phase 3 Programs
4
Upcoming Catalysts
2
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
3 upcoming, 1 past
Topotecan Phase 3 Est. Readout
Estimated primary completion for Topotecan trial (NCT06498479) in Small Cell Lung Cancer. Topline data typically follows completion by weeks to months.
Median overall survival of 18.5 months achieved
Source2 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
HS-20093
Metastasis Castration Resistant Prostate Cancer(mCRPC)
Gemcitabine combined with docetaxel
Osteosarcoma
Almonertinib
Lung Cancer
Topotecan
Small Cell Lung Cancer
HS-10566
High-risk Non-muscle-invasive Bladder Cancer
HS-20094
Overweight and Obesity
HS-10542
Paroxysmal Nocturnal Hemoglobinuria
HS-20089
Ovarian Cancer
HS-10380 Low Dose
SCHIZOPHRENIA 1 (Disorder)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
HS-20093 | Phase 3 | Metastasis Castration Resistant Prostate Cancer(mCRPC) | - | - |
Gemcitabine combined with docetaxel | Phase 3 | Osteosarcoma | - | - |
Almonertinib | Phase 3 | Lung Cancer | - | - |
Topotecan | Phase 3 | Small Cell Lung Cancer | - | - |
HS-10566 | Phase 2 | High-risk Non-muscle-invasive Bladder Cancer | - | - |
HS-20094 | Phase 2 | Overweight and Obesity | - | - |
HS-10542 | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria | - | - |
HS-20089 | Phase 2 | Ovarian Cancer | - | - |
HS-10380 Low Dose | Phase 2 | SCHIZOPHRENIA 1 (Disorder) | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Hansoh Pharmaceutical Group Co Limited/ADR's drug pipeline?→
CatalystAlert tracks 9 drug candidates in Hansoh Pharmaceutical Group Co Limited/ADR's (HNPHY) pipeline across Phase 3, Phase 2. Its lead program is HS-20093 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Hansoh Pharmaceutical Group Co Limited/ADR's next FDA catalyst?→
Hansoh Pharmaceutical Group Co Limited/ADR's (HNPHY) next tracked catalyst is a Phase 3 expected December 31, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track HNPHY biotech catalysts?→
Add HNPHY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Hansoh Pharmaceutical Group Co Limited/ADR's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.